Advertisement
AMRN vs AVIR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Hold and AVIR is a Hold.
AMRN in -2.50% downward trend, sliding for three consecutive days on October 16, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AMRN declined for three days, in 258 of 305 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for AMRN turned negative on September 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 43 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
AMRN moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The Aroon Indicator for AMRN entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 184 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
AMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.631) is normal, around the industry mean (19.199). AMRN has a moderately high P/E Ratio (67.114) as compared to the industry average of (34.793). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). AMRN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
AVIR's Indicator enters downward trend
The Aroon Indicator for AVIR entered a downward trend on October 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 244 similar instances where the Aroon Indicator formed such a pattern. In 204 of the 244 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AVIR as a result. In 64 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
AVIR moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AVIR crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVIR advanced for three days, in 196 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
AVIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. AVIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.043) is normal, around the industry mean (26.782). P/E Ratio (10.471) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AMRN | AVIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 83 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 98 | |
PRICE GROWTH RATING 1..100 | 80 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 92 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AVIR's Valuation (63) in the Biotechnology industry is in the same range as AMRN (83) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to AMRN’s over the last 12 months.
AVIR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to AMRN’s over the last 12 months.
AMRN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as AVIR (98) in the Biotechnology industry. This means that AMRN’s stock grew similarly to AVIR’s over the last 12 months.
AVIR's Price Growth Rating (60) in the Biotechnology industry is in the same range as AMRN (80) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to AMRN’s over the last 12 months.
AVIR's P/E Growth Rating (92) in the Biotechnology industry is in the same range as AMRN (100) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to AMRN’s over the last 12 months.
| AMRN | AVIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 81% | N/A |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 78% |
| Advances ODDS (%) | 4 days ago 73% | 26 days ago 77% |
| Declines ODDS (%) | 2 days ago 85% | 2 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 0 FA rating(s) are green while AVIR’s FA Score has 0 green FA rating(s).
- AMRN’s FA Score: 0 green, 5 red.
- AVIR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 4 TA indicator(s) are bullish while AVIR’s TA Score has 4 bullish TA indicator(s).
- AMRN’s TA Score: 4 bullish, 5 bearish.
- AVIR’s TA Score: 4 bullish, 5 bearish.
Price Growth
AMRN (@Pharmaceuticals: Major) experienced а -5.90% price change this week, while AVIR (@Biotechnology) price change was -16.12% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.91%. For the same industry, the average monthly price growth was -4.47%, and the average quarterly price growth was +3.55%.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
Reported Earning Dates
AVIR is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.91% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IGF | 63.84 | 0.64 | +1.01% |
| iShares Global Infrastructure ETF (IGF) | |||
| LJAN | 24.73 | N/A | N/A |
| Innovator Premium Income 15 Buffer ETF - January (LJAN) | |||
| RHRX | 21.59 | -0.16 | -0.74% |
| Adaptive Tactical Rotation ETF (RHRX) | |||
| QDEC | 36.41 | -0.41 | -1.11% |
| FT Vest Nasdaq-100 Buffer ETF - December (QDEC) | |||
| SEPI | 28.42 | -0.35 | -1.22% |
| Shelton Equity Premium Income ETF | |||
AMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | -2.16% | ||
| CNTB - AMRN | 55% Loosely correlated | +0.01% | ||
| HRTX - AMRN | 44% Loosely correlated | -4.12% | ||
| MGNX - AMRN | 44% Loosely correlated | -3.56% | ||
| ALXO - AMRN | 43% Loosely correlated | +6.00% | ||
| ARWR - AMRN | 40% Loosely correlated | -4.44% | ||
More | ||||